Long-term protection after hepatitis B vaccination in people living with HIV

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLARA, Amanda Nazareth
dc.contributor.authorSARTORI, Ana Marli
dc.contributor.authorFONSECA, Marise Oliveira
dc.contributor.authorLOPES, Marta Heloisa
dc.date.accessioned2017-10-24T13:18:19Z
dc.date.available2017-10-24T13:18:19Z
dc.date.issued2017
dc.description.abstractBackground: Hepatitis B vaccine is important in people living with HIV (PLHIV) since both viruses have the same transmission routes and co-infection has greater morbidity. PLHIV usually have poor response to hepatitis B vaccine. The duration of immunity in PLHIV is unknown. The objective of this study is to evaluate the duration of serological response and clinical protection provided by hepatitis B vaccination in PLHIV. Methods: Retrospective study of a PLHIV cohort primarily vaccinated for hepatitis B virus (HBV) from 2001 to 2002. Markers of infection and protection from HBV were investigated in those individuals who were still attending the outpatient clinic, in sao Paulo, Brazil from 2012 to 2014. Three groups were analyzed. Group 1: adults who responded to primary vaccine series. Group 2: non-responders to primary vaccine series. Group 3: subjects from both Groups 1 and 2 who did not receive any booster doses after seroconversion. Results: A cohort of 121 PLHIV was analyzed for seroconversion and persistence of anti-HBs. The majority were female (54.5%) and mean age was 50.1 years. After 11 years, none of the patients had serologic evidence of HBV infection. Overall, 41/58 (70.7%) of the initial responders (Group 1) had maintained anti-HBs >= 10 mIU/mL. Greater CD4+ values and anti-HBs > 100 mIU/mL at the time of first vaccine series were associated with persistence of anti-HBs. During the time of evaluation, 35/63 (55.6%) of the initial non-responders (Group 2) successfully seroconverted (anti-HBs >= 10 mlU/mL) in response to one or more booster doses. From the time of their seroconversion, 70 of the patients did not receive any further booster doses (Group 3). After 10 years, 54/70 (77.1%) of these individuals has maintained anti-HBs > 10 mIU/mL. Conclusions: Evaluation of long-term immunity for hepatitis B in PLHIV following vaccination showed a strong persistence of anti-HBs and no serologic evidence of HBV infection. Boosters may be effective in PLHIV non-responders to primary vaccination.
dc.description.indexMEDLINE
dc.identifier.citationVACCINE, v.35, n.33, p.4155-4161, 2017
dc.identifier.doi10.1016/j.vaccine.2017.06.040
dc.identifier.eissn1873-2518
dc.identifier.issn0264-410X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21919
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofVaccine
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCI LTD
dc.subjectHepatitis B vaccine
dc.subjectHIV
dc.subjectVaccines/immunology
dc.subjectHepatitis B antibodies
dc.subjectVaccination
dc.subjectHumoral immunity
dc.subjectLong-term persistence
dc.subject.otherinfected adult patients
dc.subject.othervirus infection
dc.subject.otherimmune-response
dc.subject.otherantibody
dc.subject.otherhbv
dc.subject.otherchildren
dc.subject.othernonresponders
dc.subject.otherrevaccination
dc.subject.othercoinfection
dc.subject.otherpersistence
dc.subject.wosImmunology
dc.subject.wosMedicine, Research & Experimental
dc.titleLong-term protection after hepatitis B vaccination in people living with HIV
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalFONSECA, Marise Oliveira:Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Belo Horizonte, MG, Brazil
hcfmusp.citation.scopus9
hcfmusp.contributor.author-fmusphcAMANDA NAZARETH LARA
hcfmusp.contributor.author-fmusphcANA MARLI CHRISTOVAM SARTORI
hcfmusp.contributor.author-fmusphcMARTA HELOISA LOPES
hcfmusp.description.beginpage4155
hcfmusp.description.endpage4161
hcfmusp.description.issue33
hcfmusp.description.volume35
hcfmusp.origemWOS
hcfmusp.origem.pubmed28669615
hcfmusp.origem.scopus2-s2.0-85021353408
hcfmusp.origem.wosWOS:000406735500016
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBarros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
hcfmusp.relation.referenceBruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
hcfmusp.relation.referenceBuskin SE, 2011, WORLD J GASTROENTERO, V17, P1807, DOI 10.3748/wjg.v17.i14.1807
hcfmusp.relation.referenceCDC, GUID PREV TREAT OPP
hcfmusp.relation.referenceCornejo-Juarez Patricia, 2006, AIDS Res Ther, V3, P9, DOI 10.1186/1742-6405-3-9
hcfmusp.relation.referenceCoutinho Leticia M S, 2008, Rev. Saúde Pública, V42, P992, DOI 10.1590/s0034-89102008000600003
hcfmusp.relation.referenceCruciani M, 2009, VACCINE, V27, P17, DOI [10.1016/j.vaccine.2008.10.040, 10.1016/j.vacine.2008.10.040]
hcfmusp.relation.referenceDavies HTO, 1998, BRIT MED J, V316, P989
hcfmusp.relation.referencede Vries-Sluijs TEMS, 2008, J INFECT DIS, V197, P292, DOI 10.1086/524690
hcfmusp.relation.referenceBalado MDD, 2010, J INFECT DIS, V202, P362, DOI 10.1086/653707
hcfmusp.relation.referenceFonseca MO, 2005, VACCINE, V23, P2902, DOI 10.1016/j.vaccine.2004.11.057
hcfmusp.relation.referenceHepatitis B, 2009, WKLY EPIDEMIOL REC, V84, P405
hcfmusp.relation.referenceIrungu E, 2013, J INFECT DIS, V207, P402, DOI 10.1093/infdis/jis695
hcfmusp.relation.referenceJack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
hcfmusp.relation.referenceJarrosson L, 2004, VACCINE, V22, P3789, DOI 10.1016/j.vaccine.2004.02.046
hcfmusp.relation.referenceKim JH, 2012, GUT LIVER, V6, P86, DOI 10.5009/gnl.2012.6.1.86
hcfmusp.relation.referenceLao-araya M, 2011, VACCINE, V29, P3977, DOI 10.1016/j.vaccine.2011.03.077
hcfmusp.relation.referenceLaunay O, 2011, JAMA-J AM MED ASSOC, V305, P1432, DOI 10.1001/jama.2011.351
hcfmusp.relation.referenceLopes VB, 2013, VACCINE, V31, P1040, DOI 10.1016/j.vaccine.2012.12.047
hcfmusp.relation.referenceMast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1
hcfmusp.relation.referenceMayaphi SH, 2012, SAMJ S AFR MED J, V102, P157
hcfmusp.relation.referenceMena G, 2012, VACCINE, V30, P3703, DOI 10.1016/j.vaccine.2012.03.018
hcfmusp.relation.referenceMS/SVS/DVDT, MAN CTR REF IM ESP
hcfmusp.relation.referenceNi JD, 2013, INT J STD AIDS, V24, P117, DOI 10.1177/0956462412472309
hcfmusp.relation.referencePessoa SD, 2010, VACCINE, V28, P1606, DOI 10.1016/j.vaccine.2009.11.045
hcfmusp.relation.referencePhung BC, 2014, WORLD J GASTROENTERO, V20, P17360, DOI 10.3748/wjg.v20.i46.17360
hcfmusp.relation.referencePippi F, 2008, HIV MED, V9, P519, DOI 10.1111/j.1468-1293.2008.00598.x
hcfmusp.relation.referencePowis JE, 2012, J INFECT DIS, V205, P1534, DOI 10.1093/infdis/jis243
hcfmusp.relation.referenceRey D, 2000, VACCINE, V18, P1161, DOI 10.1016/S0264-410X(99)00389-8
hcfmusp.relation.referenceRouet F, 2008, CLIN INFECT DIS, V46, P361, DOI 10.1086/525531
hcfmusp.relation.referenceSoriano V, 2013, CLIN LIVER DIS, V17, P489, DOI 10.1016/j.cld.2013.05.008
hcfmusp.relation.referenceSpradling PR, 2010, J VIRAL HEPATITIS, V17, P879, DOI 10.1111/j.1365-2893.2009.01249.x
hcfmusp.relation.referenceThibault V, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-87
hcfmusp.relation.referenceYang R, 2011, INFECTION, V39, P427, DOI 10.1007/s15010-011-0145-1
hcfmusp.scopus.lastupdate2024-05-18
relation.isAuthorOfPublication19d365e2-d108-4ec9-b7f9-13f46a5574da
relation.isAuthorOfPublicationf7c6e3e7-9e8f-4c2a-98d5-4b94881dfb25
relation.isAuthorOfPublication2178f817-7741-4b9a-9908-13ed65ab349c
relation.isAuthorOfPublication.latestForDiscovery19d365e2-d108-4ec9-b7f9-13f46a5574da
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_LARA_Longterm_protection_after_hepatitis_B_vaccination_in_people_2017.PDF
Tamanho:
287.78 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05